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in LNCaP cells, and it was c-Jun and c-Fos in case of PC-3 
cells, while bicalutamide decreased their expression. In 
addition, constitutive activation and non-regulation of 
Fra-1 by bicalutamide in PC-3 cells suggested that Fra-1, 
probably a key component, involved in transition of aggres-
sive androgen-independent PC-3 cells with poor prognosis.
Keywords Androgen receptor · Dihydrotestosterone · 
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Introduction
Prostate cancer (PCa) is the most pervasive malignancy 
diagnosed and remains the second leading cause of cancer-
related mortality affecting men in Western countries [1]. 
The central role of androgens in the regulation of growth, 
differentiation, and death responses in both normal and 
cancerous prostate tissue is well recognized [2–4]. The 
cellular effect of androgens is mediated via the androgen 
receptor (AR), a ligand-activated transcription factor and 
a member of the nuclear receptor superfamily. AR is com-
posed of an N-terminal domain (NTD) which contains a 
major activation domain, AF-1, a DNA-binding domain 
(DBD), a hinge region, and a C-terminal ligand-binding 
domain (LBD) containing a weak activation domain, AF-2 
[5]. Unliganded AR is sequestered in the cytoplasm by heat 
shock proteins. AR upon binding to a hormone (testoster-
one or dihydrotestosterone-DHT) dissociates the heat shock 
proteins and translocates them into nucleus. Androgen–AR 
complex functions as a transcription factor that binds as a 
homodimer to the androgen-response element (ARE) pre-
sent in the regulatory elements of target genes promoting 
transcription. Hence, the androgen receptor acts as a key 
protein in prostate cancer progression. It is upregulated in 
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all the stages of the disease by gene amplification or by 
other, non-genomic mechanism of action [6, 7]. Many stud-
ies have shown that the inhibition of AR activity could be 
an effective approach for prostate cancer treatment. Andro-
gen deprivation therapy (ADT) using AR antagonist rep-
resents a first-line treatment strategy for advanced, recur-
rent, and even metastatic prostate cancer [8]. Bicalutamide 
(BIC), a non-steroidal anti-androgen molecule, finds use in 
the treatment of locally advanced and metastatic prostate 
cancer. The drug BIC became popular owing to its toler-
able side effect profile, ease of administration with long 
half-life, and offers an attractive alternative to the steroidal 
anti-androgens. It functions as a receptor antagonist and 
prevents the binding of DHT [9, 10]. Despite the success 
of ABT, most tumors eventually relapse and develop into 
castration-resistant prostate cancer (CRPC) due to the aber-
rant restoration of AR activity [11]. AR is involved in the 
transcriptional regulation of prostate-specific marker genes 
such as prostate-specific antigen (PSA) and transmembrane 
protease serine 2 (TMPRSS2), and their expression corre-
lates with tumor size and progression to next stage in pros-
tatic cancer [12]. Hence, understanding the changes in AR 
signaling in the evolution of androgen-independent prostate 
cancer will be a key to the development of more effective 
hormone therapy.
Activator protein-1 (AP-1) contributes to the develop-
ment and progression of prostatic malignancies by regulat-
ing the expression of genes involved in proliferation, apop-
tosis, and angiogenesis, as well as in tumor invasion and 
metastasis [13, 14]. AP-1 transcription factors comprise a 
ubiquitously expressed family of proteins that include the 
Jun (e.g., c-Jun, Jun-B, Jun-D), Fos (e.g., c-Fos, Fos-B, 
Fra-1, Fra-2), ATF activating transcription factor (ATF2, 
LRFI/ATF3), and MAF musculoaponeurotic fibrosarcoma 
(c-Maf, MafB, MafA, MafG/F/K) proto-oncoproteins. The 
main AP-1 proteins in mammalian cells are Fos and Jun, 
which form hetero-(Jun–Fos or Jun–Fra) or homodimers 
(Jun–Jun) complex [15, 16]. The number of combination 
of Jun (c-Jun, Jun-D, Jun-B) and Fos (c-Fos, Fos-B, Fra-
1, Fra-2) creates an enormous functional diversity with 
individual AP-1 proteins probably engaged in different cell 
functions [17]. They interact via a leucine-zipper domain 
and bind to AP-1 consensus sequence known as TPA-
responsive elements (TREs) TGA(C/G) TCA or Cyclic 
AMP-responsive elements (CREs) TGA CGT CA. This ele-
ment is known to be present within the regulatory region of 
several genes including c-Jun [18]. The AP-1 complex acts 
as a “signal converter” [19], which mediates responses to 
cellular signals by binding to DNA and producing changes 
in gene transcription that ultimately lead to physiological 
changes of a cell.
The cellular changes regulated by androgen receptor due 
to androgen DHT and anti-androgen BIC exposure may 
result in change of the cellular reduction/oxidation (redox) 
state in human prostate cancer cells [20]. These may in 
turn affect the transcription factors that are sensitive to cel-
lular redox status, such as the AP-1 transcription factors 
[21]. Additionally, both transrepressive and transactivat-
ing cross-talk may occur between the androgen receptor 
and AP-1 [22]. Different AP-1 factors’ expression pattern 
is a stage- and tissue-specific, and may be fundamental to 
the process of oncogenesis. Interestingly, it has been sug-
gested that Fos and Jun proteins were clearly elevated in 
androgen-independent tumors in a mouse model [23]. Stud-
ies from our laboratory suggested that c-Jun, c-Fos, and 
Fra-1 were elevated in breast cancer MCF-7 cells and that 
may be attributed to their actions on estrogen receptor [24]. 
Thus, regulating AP-1 activity with respect to AR may be 
an important event in prostate cancer development and 
progression.
Hence, in the present study, we investigated the role of 
androgen DHT and anti-androgen BIC on the expression 
patterns of AR, AR target genes, AP-1 factors, and their 
effect on cell cycle regulators and apoptotic genes using 
LNCaP and PC-3 cells. LNCaP cells are demonstrated to 
be androgen receptor positive with low tumorigenicity 
compared to androgen receptor negative and highly aggres-
sive tumorigenic PC-3 cells. The study provides insights 
into the role of molecular pathways, in the development of 
aggressive form of prostate cancer, and may help in identi-
fication of a target for therapeutic intervention.
Materials and methods
Materials
Human prostate cancer LNCaP and PC-3 cell lines were 
purchased from NCCS (Pune, India); dihydrotestoster-
one (DHT), bicalutamide (BIC),  TRIzol, Oligo’s for-
ward and reverse primers for different AP-1 factors, AR, 
PSA, TMPRSS2, β-actin, cell cycle regulators, and apop-
totic genes (Table  1) were designed and purchased from 
Sigma-Aldrich (St. Louis, USA). Fetal bovine serum 
(FBS), penicillin, streptomycin, glutamine, RPMI 1640 
medium, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazo-
lium bromide (MTT), dimethyl sulfoxide (DMSO), trypan 
blue, agarose, and Ethidium bromide were purchased 
from Himedia (Mumbai, India). OligodTs and superscript 
reverse transcriptase were obtained from Invitrogen BioS-
ervices India Pvt. Ltd (Bangalore, India); Antibodies of 
GAPDH, AR, and Fra-1 were purchased from NeoBiolab 
(MA, USA), and anti-rabbit antibody-HRP conjugate was 
Mol Cell Biochem 
1 3
purchased from Imgenex India Pvt. Ltd. (Bhubaneswar, 
India). Taq DNA polymerase (1 U/µl) and Luminata Forte 
Western HRP substrate were procured from Merck-Milli-
pore (Mumbai, India).
Culturing of cells
LNCaP and PC-3 Cells were grown in 25 cm2 culture flasks 
using RPMI 1640 media with 10% FBS, 100  U/ml peni-
cillin, 100  mg/ml streptomycin, and 2  mM l-glutamine. 
Table 1  Sequence of primers 
used in RT-PCR studies
Columns 3 and 4 show annealing temperatures and the size of the amplified products
F forward, R reverse
Gene Primer sequence (5′→3′) Annealing 
temp. (°C)
Product 
size (bp)
Reference
Hormonal receptor
 AR F: CGA CTA CCG CAT CAT CAC AG
R: TCT GGA AAG CTC CTC GGT AG
59 169 Present study
AR marker genes
 PSA F: AGG TCA GCC ACA GCT TCC CA
R: GGG CAG GTC CAT GAC CTT CA
58 155 Present study
 TMPRSS2 F: AGG TGC ATC CGG CTC AGT A
R:GGG TCA AGG TGA TGC ACA GT
62 159 Present study
AP-1 factors
 c-Jun F: GCC TAC AGA TGA ACT CTT TCT GGC 
R: CCT GAA ACA TCG CAC TAT CCT TTG 
64 525 [27]
 Jun-D F: CGC AGC CTC AAA CCC TGC CTT TCC 
R: AAA CAG GAA TGT GGA CTC GTAG
64 500 [27]
 Jun-B F: CCA GTC CTT CCA CCT CGA CGT TTA CAAG
R: GAC TAA GTG CGT GTT TCT TTT CCA CAG TAC 
58 257 [27]
 c-Fos F: TCT TCC TTC GTC TTC ACC 
R: AAT CAG AAC ACA CTA TTG CC
58 577 [27]
 Fra-1 F: AGG AAG GAA CTG ACC GAC 
R: GAA GGG GAG GAG ACA TTG 
60 497 [27]
 Fra-2 F: AGG AGG AGA GAT GAG CAG 
R: GGA TAG GTG AAG ACG AGG 
60 518 [27]
 Fos-B F: TGT CCC AGG GAA ATG TTT CAGGC
R: ACT GGT AGT TCC GCT GGT GGA AGG 
56 451 Present study
Cell cycle regulators
 P53 F: GAG CCC CCT CTG AGT CAG 
R: GCA AAA ACA TCT TGT TGA G
56 375 [27]
 P21 F: GAT CAC AAG CAG TGG GGT GA
R:CTG AGT GAC TGC ACG ACC TT
58 160 Present study
 CDK4 F: AGT GGC GGA TCC ATG GCT ACC TCT CGA TAT 
R: TCT CGG AAG CTT TCA CTC CGG ATT ACC TTC A
60 912 [27]
 Cyclin D1 F: AGA CCT GCG CGC CCT CGG TG
R: GTA GTA GGA CAG GAA GTT GTTG
58 574 [27]
 Cyclin E1 F: GTC CTG GCT GAA TGT ATA CATGC
R: CCC TAT TTT GTT CAG ACA ACAT
60 415 [27]
Apoptotic genes
 Bcl-2 F: AGA TGT CCA GCC AGC TGC ACC TGA C
R: AGA TAG GCA CCC AGG GTG ATG CAA GCT
62 365 [27]
 Bax F: AAG CTG AGC GAG TGT CTC AAG CGC 
R: TCC CGC CAC AAA GAT GGT CACG
61 366 [27]
 Caspase-8 F: GAT ATT GGG GAA CAA CTG GAC
R: CAT GTC ATC ATC CAG TTT GCA
58 366 Present study
 Caspase-3 F: TTA ATA AAG GTA TCC ATG GAG AAC ACT
R: TTA GTG ATA AAA ATA GAG TTC TTT TGT GAG 
59 848 Present study
 β-actin F: TAC CAC TGG CAT CGT GAT GGACT
R: TCC TTC TGC ATC CTG TCG GCAAT
62 516 [27]
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The cells were cultured in an incubator under humidified 
atmosphere at 37 °C by passing 5% CO2. Flask containing 
90–100% confluent cells were sub-cultured in 96-well plate 
(3 ×  103  cells/well) and in a 6-well plate (5 × 105  cells/
well), for the treatment and expression studies.
MTT assay
Analysis of cell viability was carried out using MTT assay 
as per the protocol described earlier [25]. MTT is a pale 
yellow substrate taken up by live cells and reduced in mito-
chondria by Succinate dehydrogenase to yield a dark blue 
formazan product. LNCaP or PC-3 cells (3 × 103  cells/
well) in RPMI-1640 medium in a volume of 200 μl were 
seeded into a 96-well culture plate and incubated over-
night at 37 °C with the supply of 5% CO2. Cells were 
treated with or without different concentrations of DHT 
or BIC and incubated further for 48  h. The cells were 
washed with PBS, and treated with 20 μl of MTT (5 mg/
ml) and incubated for 4 h at 37 °C in a CO2 incubator. The 
blue formazan products formed in cells were dissolved in 
DMSO (100  μl) and spectrophotometrically measured at 
540  nm. The effect of DHT or BIC on cell viability was 
calculated and represented graphically as % of viable cells 
compared to control.
RNA isolation and semi-quantitative RT-PCR analysis
Overnight cultures of LNCaP or PC-3 cells (5 × 105 cells/
well) in a six-well plate were incubated with or without 
DHT (10 nM) or BIC (50 or 75 µM) for 48 h. Total RNA 
was isolated from control, and treated cells using TRIzol 
reagent as per the protocol standardized in the laboratory 
and instructions provided by the manufacturer. Reverse 
transcription of RNA and PCR analysis were carried out as 
per the protocol described earlier [26]. Total RNA (2 μg) of 
different samples was reverse-transcribed using Oligo (dT) 
primers and superscript reverse transcriptase. The comple-
mentary DNA (cDNA) was subjected to 30 cycles of PCR 
in a gradient Eppendorf thermo cycler using different for-
ward and reverse primers of genes of AR, PSA, TMPRSS2, 
AP-1 factors, cell cycle regulators, and apoptotic regulators 
(Table 1) as described earlier [27]. The β-actin was used as 
a positive control and for normalization. First-strand cDNA 
(1  µl) was mixed with 2  µl of 10x PCR buffer (200  mM 
Tris–HCl pH 8.4, 500  mM KCl), 1  µl of 50 mMMgCl2, 
1 µl each of 10 pmol of forward and reverse primers, 1 µl 
of 10 mM dNTP’s, and one unit of Taq DNA polymerase 
in a volume of 20 µl reaction mixture. PCR amplification 
conditions used were initial denaturation at 94 °C for 5 min 
followed by 30 cycles with 94 °C for 1 min, specific anneal-
ing temperatures (Table  1) for 1  min, elongation at 72 °C 
for 50  s, and a final extension cycle at 72 °C for 7  min. 
Amplified PCR products were analyzed by electrophoresis 
using 1% agarose gels and 1× TAE electrode buffer.
Western blot analysis of AR and Fra-1
LNCaP or PC-3 cells (5 × 105 cells/well) in a six-well plate 
were incubated with or without DHT (10 nM) or BIC (50 
or 75 μM) for 48 h and subjected to western blot analysis as 
described earlier [27] with minor modifications. Cells were 
lysed in 0.2 ml of cold lysis buffer [Tris–HCl (50 mM) pH 
8.0, NaCl (150 mM), NP-40 (1.0%), and PMSF (100 µM)]. 
Protein concentrations of cell lysates were measured by 
Bradford’s method [28]. Equal amounts of protein (40 μg/
lane) were electrophoresed on 4‒12% sodium dodecyl sul-
fate–polyacrylamide gel and transferred onto PVDF mem-
brane. Membrane was blocked with 5% Carnation fat-free 
milk for 1 h at room temperature. Blots were incubated with 
primary antibody (anti AR and Fra-1) in blocking solu-
tion (1:500) for 1 h, washed and incubated with anti-rabbit 
antibody-HRP (1:1000), and further incubated for 1  h at 
room temperature. Proteins were visualized using Luminata 
Forte Western HRP substrate and as per the specifications 
provided by the supplier in a Syngene Gel Documentation 
system (MD, USA). GAPDH was used as an internal con-
trol for normalization. Immunoreactive bands were quanti-
fied using image analysis software (Image J).
Statistical analysis
The experimental data are shown as mean ± SD from at 
least three independent experiments. Statistical analysis 
was done by Student’s t test and one-way ANOVA, fol-
lowed by post hoc Tukey test, and values were considered 
as statistically significant if *P < 0.05, **P < 0.005 com-
pared to control, and if #P < 0.05 compared to DHT-treated 
sample.
Results
Dihydrotestosterone (DHT) induces proliferation 
of LNCaP cells
To study the effect of DHT on cell growth, the LNCaP 
cells or PC-3 cells were treated with or without differ-
ent concentrations of DHT (1–100 nM) for 48 h, and cell 
viability was determined by MTT assay. The results show 
that only in androgen-positive LNCaP cells, the cell num-
ber increases with increased concentration of DHT in a 
dose-dependent manner. The significant increase in cell 
number (18%) was observed at 25  nM concentration of 
DHT (P > 0.05) and the cell number remained almost 
same at higher concentrations of DHT (25 and 100 nM) 
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(Fig.  1a). Similar results were obtained by counting the 
viable cells using trypan blue dye exclusion method (data 
not shown) in a Neubauer counting chamber. However, 
in androgen-negative PC-3 cells, the DHT at all con-
centrations found to have little or no effect in cell num-
ber (Fig.  1b). The results confirm that LNCaP cells are 
androgen-responsive, while PC-3 cells were androgen-
non-responsive cells.
Bicalutamide (BIC), an anti-androgen, reduces 
the viability of both LNCaP and PC-3 cells
To study cytotoxic effect of anti-androgen BIC on cells, the 
LNCaP or PC-3 cells were treated with or without different 
concentrations of BIC (10–100 μM) for 48 h, and cell via-
bility was determined by MTT assay. Results show that 
BIC decreases the cell viability of both LNCaP and PC-3 
cells in a dose-dependent manner. The statistically signifi-
cant decrease of 25 and 17% was observed at 25 and 50 µM 
concentration of BIC in LNCaP and PC-3 cells, respec-
tively. (Fig. 2a, b). The similar results and dose-dependent 
response of decrease in both LNCaP and PC-3 cells were 
observed by counting viable cells using dye exclusion 
method (data not shown). Note that the inhibitory effect 
of BIC was more effective in LNCaP as the  IC50 of BIC 
was found to be 68 µM compared to 100 μM in PC-3 cells. 
However, the BIC significantly decreases cell viability in 
both LNCaP and PC-3 cells.
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Fig. 1  Effect of DHT on the proliferation of (a) LNCaP cells and (b) 
PC-3 cells. LNCaP or PC-3 cells were treated with or without differ-
ent concentrations of DHT (1–100 nM) in a 96-well plate for 48 h, 
and the growth of the cells was analyzed by MTT assay. Results were 
expressed as % viability of cells compared to control (mean ± SD, 
n = 8). Values are significantly different from control if *P < 0.05, 
**P < 0.005 by student t test, one-way anova, and post hoc Tukey test. 
The results are shown as a representative of three independent experi-
ments
(a) (b) 
0
20
40
60
80
100
120
Control 10 25 50 75 100
%
 V
ia
bi
lit
y 
of
 ce
lls
Concentration of Bicalutamide (µM)
**
**
**
*
*
0
20
40
60
80
100
120
Control 10 25 50 75 100
%
 V
ia
bi
lit
y 
of
 c
el
ls
Concentration of Bicalutamide (µM)
Fig. 2  Effect of BIC on the viability of (a) LNCaP cells and (b) 
PC-3 cells. LNCaP or PC-3 cells were treated with or without differ-
ent concentrations of BIC (10–100 µM) in a 96-well plate for 48 h, 
and the cell viability was determined by MTT assay. Results were 
expressed as % viability of cells compared to control (mean ± SD, 
n = 8). Values are significantly different from control if *P < 0.05, 
**P < 0.005 by student t test, followed by one-way anova and post 
hoc Tukey test. The results are shown as a representative of three 
independent experiments
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DHT induces but BIC reduces the mRNA expression 
of AR in LNCaP cells
To assess the effect of DHT and BIC on the expression of 
them RNAs of AR in LNCaP or PC-3 cells, the cells were 
treated with or without DHT or BIC and RNA levels were 
analyzed by semi-quantitative RT-PCR. Results show that 
the LNCaP cells treated with DHT (10  nM) induced the 
AR mRNA expression by more than 1.75-fold compared to 
control, while cells treated with BIC (50 µM) decreased the 
mRNA expression of AR by more than 52% compared to 
control (Fig. 3a). However, PC-3 cells show very negligi-
ble amount of AR mRNA transcripts both in control as well 
as in DHT- or BIC-treated samples (Fig. 3b). Results sug-
gested that LNCaP cells are androgen-responsive and AR-
positive cells, while PC-3 cells are androgen-non-respon-
sive and AR-negative cells.
BIC significantly inhibits the expression 
of androgen-regulated genes (PSA and TMPRSS2) 
in LNCaP cells
To analyze the effect of DHT and BIC on the expres-
sion of AR-regulated marker genes(prostate-specific 
antigen (PSA) and transmembrane protease serine 2 
(TMPRSS2)), the LNCaP and PC-3 cells were treated 
with DHT and BIC, and the mRNA levels of PSA and 
TMPRSS2 were analyzed by semi-quantitative RT-PCR. 
Results show that the AR-positive LNCaP cells treated 
with DHT induced mRNA expression of PSA by more 
than 0.8-fold, and no significant induction was seen with 
TMPRSS2m RNAs, While BIC significantly decreased 
the expression of mRNAs of both PSA and TMPRSS2 by 
54 and 76%, respectively, compared to control (Fig. 4a).
However, in AR-negative PC-3 cells, DHT marginally 
induced mRNAs of both PSA and TMPRSS2 and BIC 
decreased marginally the expression of mRNAs of PSA 
and TMPRSS2 genes (Fig. 4b).The differential expression 
of AR-regulated genes with the treatment in LNCaP and 
PC-3 cells may be due to difference in their AR status.
Differential expression of mRNAs of AP-1 factors 
in LNCaP and PC-3 cells
To analyze the effect of androgen and anti-androgen on 
the expression of mRNA levels of different AP-1 factors in 
LNCaP and PC-3 cells, the cells were treated with or with-
out DHT(10 nM) or BIC (50 and 75 µM)for 48 h and the 
total RNA was subjected to RT-PCR. The results show that 
the Jun (c-Jun, Jun-B, and Jun-D) and Fos (c-Fos, Fra-1, 
Fra-2, and Fos-B) family member mRNA transcripts were 
expressed at different levels in both LNCaP and PC-3 cells. 
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Fig. 3  Effect of DHT and BIC on the mRNA levels of AR in (a) 
LNCaP cells and (b) PC-3 cells. LNCaP or PC-3 cells (5 × 105 cells/
well) were treated with or without DHT (10  nM) or BIC (50 or 
75 μM) for 48 h. The cDNA was prepared from total RNA and sub-
jected to 30 cycles of PCR using specific primers of AR. Expression 
of β-actin was used as a positive control and for normalization. The 
mRNA levels of AR were analyzed on 1% agarose gel. Data represent 
mean ± SD from three independent experiments. *P < 0.05 compared 
to control cells and #P < 0.05 in compared to DHT-treated condition 
values using one-way ANOVA followed by post hoc Tukey test. The 
bar graph represents the densitometric analysis of mRNA levels of 
AR
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In LNCaP cells, DHT induced c-Jun and Fra-1 mRNAs sig-
nificantly by 1.5- and 1.75-fold, respectively, and decreased 
the expression of Fra-2 by 31% compared to control 
(Fig. 5a). However, BIC significantly decreased the mRNA 
transcripts of c-Jun by 25%, Fra-1 by 48%, and Fos-B by 
51%, and increased the gene expression of Jun-D by 1.9-
fold compared to control (Fig.  5a). In PC-3 cells, DHT 
significantly induced the expression of c-Jun by onefold 
and c-Fos by 1.7-fold and also marginally decreased the 
expression of Fra-2 and Fos-B mRNA transcripts by 18 and 
16%, respectively, compared to control (Fig. 5b). The treat-
ment with BIC significantly decreased the gene expression 
of c-Jun by 25% and c-Fos by 51% and also increased the 
expression of Fra-2 and Fos-B mRNA transcripts by 0.9- 
and 0.8-fold, respectively, compared to control. However, 
both DHT and BIC show no effect on the expression of 
Jun-D and Fra-1 mRNAs (Fig. 5b). The results suggested 
that there is a difference in the expression of individual 
AP-1 factors between LNCaP and PC-3 cells, and therefore 
the expression of individual AP-1 factors is probably stage-
specific, playing a major role in the development of CRPC.
DHT induces but BIC inhibits the expression of AR 
and Fra-1 proteins in LNCaP cells, and constitutive 
increased expression of Fra-1 protein in PC-3 cells
LNCaP cells treated with DHT show significant increase 
in AR and Fra-1 protein level by more than 26 and 65%, 
respectively, compared to control. BIC significantly 
decreased both control and DHT induced AR by 65 and 
75%, while Fra-1 by 40 and 55%, respectively (Fig.  6a). 
PC-3 cells exhibited negligible or null expression of AR 
and higher constitutive expression of Fra-1 proteins both in 
control as well as DHT- and BIC-treated samples (Fig. 6b).
DHT inhibits and BIC activates the co-repressor 
cyclin D1 in LNCaP cells, while BIC inhibits cyclin E1 
in both LNCaP and PC-3 cells
To study the effects of DHT and BIC on the expression of 
mRNAs levels of different cell cycle regulators in LNCaP 
and PC-3 cells, cells were treated with or without DHT (10 
nM) or BIC (50 and 70 μM) for 48 h. LNCaP cells treated 
with DHT induced cyclin E1 mRNA significantly by 
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Fig. 4  Effect of DHT and BIC on the mRNA levels of PSA and 
TMPRSS2 in (a) LNCaP cells and (b) PC-3 cells. LNCaP or PC-3 
cells (5 × 105 cells/well) were treated with or without DHT (10 nM) 
or BIC (50 or 75 μM) for 48 h. The cDNA was prepared from total 
RNA and subjected to 30 cycles of PCR using specific primers of 
PSA and TMPRSS2. Expression of β-actin was used as a positive con-
trol and for normalization. The mRNA levels of PSA and TMPRSS2 
were analyzed on 1% agarose gel. Data represent mean ± SD from 
three independent experiments. *P < 0.05 compared to control cells 
and #P < 0.05 in compared to DHT-treated condition values using 
one-way ANOVA followed by post hoc Tukey test. The bar graph 
represents the densitometric analysis of mRNA levels of PSA and 
TMPRSS2
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1.7-fold and decreased the expression of cyclin D1 by 51% 
compared to control, while the expressions of p53, p21, and 
CDK4 transcripts were unaffected (Fig. 7a). However, BIC 
treatment increased the cyclin D1 mRNA levels by 1.5-
fold, marginally increased the CDK4 transcript, and signifi-
cantly decreased the levels of cyclin E1 and p21 by 45 and 
22%, respectively. In PC-3 cells, while DHT significantly 
decreased the expression of p21 by 26% and marginally 
decreased p53 transcripts by 10%, BIC induced p53 mRNA 
marginally by 10% and p21 mRNA by 9% and significantly 
decreased (70%) cyclin E1 mRNA transcripts (Fig.  7b). 
Results suggested that BIC has a prominent effect on the 
expression of cyclin D1 in LNCaP than PC-3 cells.
BIC induces apoptotic genes in LNCaP and PC-3 cells
LNCaP cells treated with BIC induced the expression 
of mRNAs pro-apoptotic gene Bax by 1.5-fold and the 
initiator Caspase-8 by 0.8-fold. BIC also decreased the 
expression of anti-apoptotic Bcl2 by 38% in LNCaP cells 
(Fig.  8a). However, in PC-3 cells, BIC increased the 
expression of mRNAs of Bax, Caspase-8, and Caspase-3 by 
1-, 0.7-, and 0.8-fold, respectively, and significant decrease 
was observed with Bcl2 by 45%, compared to control 
(Fig.  8b). DHT induced the expression of anti-apoptotic 
Bcl2 marginally by 10 and 18%, and had no effect on Bax, 
Caspase-8, and Caspase-3 in LNCaP and PC-3 cells. Result 
suggested that BIC induced apoptotic genes in both LNCaP 
and PC-3 cells.
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Fig. 5  Expression pattern of mRNAs of AP-1 factors (Jun and 
Fos family) in (a) LNCaP cells and (b) PC-3 cells. LNCaP or PC-3 
cells(5 × 105 cells/well) treated with or without DHT (10 nM) or BIC 
(50 and 75 µM) for 48 h in 6-well plate. Total RNA was isolated from 
control and treated cells. cDNA was prepared by RT and subjected 
to 30 cycles of PCR using specific primers of Jun and Fos family 
members. Expression of β-actin was used as a positive control and 
for normalization. Data shown are means ± SD from three independ-
ent experiments. Differences in AP-1 factors of mRNA levels are sta-
tistically significant: if *P < 0.05 compared to control cells, #P < 0.05 
compared with DHT-treated condition values using one-way ANOVA 
followed by post hoc Tukey test. The bar graph represents the densi-
tometric analysis of mRNA levels of AP-1 factors
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Discussion
The progression of prostate cancer has been found to be 
androgen-dependent with androgen playing a key role in 
the proliferation, differentiation, and survival of prostate 
cancer cells [29, 30]. The effect of androgens is mediated 
through the androgen receptor (AR), a ligand-modulated 
transcription factor belonging to a nuclear receptor super-
family that regulates its targeted gene expression [31, 32]. 
Early studies documented well that AR played complicated 
yet vital roles in the progression of PCa. Importantly, AR 
could either stimulate or suppress PCa progression via 
modulating cell proliferation or cell death with distinct 
mechanisms [33–35]. As a therapeutic modality for PCa, 
androgen deprivation therapy (ADT), which suppresses or 
interferes with the activity of the AR especially through 
the use of anti-androgens, is a well-known treatment strat-
egy for prostate cancer [8]. Despite an initial favorable 
response, almost all patients invariably progress to a more 
aggressive, castrate-resistant phenotype. Considerable evi-
dence now supports the concept that development of CRPC 
is causally related to continued transactivation of AR. The 
androgen receptor is involved in the transcriptional regula-
tion of endogenous androgen-regulated prostate-specific 
marker genes such as PSA and TMPRSS2 which are used 
to monitor treatment responses, prognosis, and progression 
as their concentrations correlate with tumor size in prostatic 
cancer [36, 37]. BIC is a non-steroidal anti-androgen used 
in the treatment of locally advanced and metastatic pros-
tate cancer. Owing to its tolerable side effect profile, ease 
of administration, and long half-life, it offers an attractive 
alternative strategy compared to the steroidal anti-andro-
gens [38]. However, the mechanism by which BIC induces 
apoptosis remains unclear. Defining exact pathways or pre-
cise cellular mechanism by which BIC induces its apoptotic 
effects would enhance our understanding of its role in pros-
tate cancer. Promoting apoptosis in advanced disease with 
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Fig. 6  Effect of DHT and BIC on the expression of AR and Fra-1 
protein levels in (a) LNCaP cells and (b) PC-3 cells. LNCaP or 
PC-3 cells were treated with or without DHT (10 nM) or BIC (50 
or 75  μM) for 48  h. Cell lysates were prepared using lysis buffer 
and equal amounts of protein (40  μg) of cell lysates were analyzed 
by SDS-PAGE, transferred to PVDF membrane, and western blot-
ting was carried out using AR, Fra-1, and GAPDH antibodies. The 
expressed protein level of GAPDH was used as control. Data repre-
sent mean ± SD from three independent experiments. Differences in 
protein levels are statistically significant: if *P < 0.05 compared to 
control cells and #P < 0.05 in compared to DHT-treated condition val-
ues using one-way ANOVA followed by post hoc Tukey test. The bar 
graph represents the densitometric analysis of protein levels
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BIC would represent a major therapeutic breakthrough for 
prostate cancer research.
In the present study, we have chosen two cell lines rep-
resenting the hormonal therapeutic spectrum of prostate 
cell physiology: first the LNCaP cells, which are benign, 
androgen sensitive, and receptor positive, and second 
the PC-3 cells, which are derived from malignant pros-
tate tissue and are androgen-independent. Comparing the 
effect of DHT or BIC on these two cell lines mirrors the 
clinical dilemma of hormonal treatment. In our initial 
experiments, the effect of DHT and BIC was evaluated on 
cell viability of LNCaP and PC-3 cells. Consistent with 
the findings of Horoszewicz et  al. [39], DHT induced 
cell proliferation of LNCaP cells and showed no effect 
on PC-3 cells, suggesting that LNCaP cells are androgen-
responsive and PC-3 are androgen-non-responsive cells 
(Fig.  1a, b). However, BIC decreases the cell viability 
of both LNCaP and PC-3 cells. However, the androgen-
independent PC-3 cells showed a less marked apoptotic 
response to BIC as compared to the androgen-dependent 
LNCaP cell line (Fig.  2a, b). This represented an inter-
esting finding that a drug (BIC) that ostensibly acts as a 
receptor antagonist induced cell death in a receptor-neg-
ative cell line. Our results are in good agreement with 
earlier studies reported by Jing Li et  al. [40], wherein a 
high dose of BIC inhibited growth curves in androgen 
receptor-negative PC-3 cells, although the method of cell 
death was thought to be cytotoxic and also receptor-inde-
pendent [41].
Our studies further investigated the occurrence of AR 
expression in LNCaP and PC-3 cells. LNCaP signifi-
cantly expressed AR and DHT upregulated AR transcripts, 
whereas BIC suppressed AR transcripts confirming them 
as androgen-responsive cells. Our results are in good agree-
ment with the findings of Lee et al. [42] who also reported 
that DHT induced the AR transcriptional level in LNCaP 
cells. However, in PC-3 cells, there was only a mere or 
null expression of AR transcripts which confirms them 
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Fig. 7  Effects of DHT and BIC on the expression of mRNAs of cell 
cycle regulators in (a) LNCaP cells and (b) PC-3 cells. LNCaP or 
PC-3 cells(5 × 105 cells/well) were treated with or without DHT (10 
nM) or BIC (50 and 75 µM) for 48 h in a 6-well plate. Total RNA 
was isolated from cells and cDNA was prepared by RT and subjected 
PCR using specific primers of cell cycle regulators. Expression of 
β-actin was used as a positive control and for normalization. Data 
shown are mean ± SD from three independent experiments. Differ-
ence in cell cycle regulators mRNA levels are statistically significant: 
if *P < 0.05 compared to control cells, #P < 0.05 compared with DHT-
treated condition values using one-way ANOVA followed by post hoc 
Tukey test. The bar graph represents the densitometric analysis of 
mRNA levels of cell cycle regulators
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as androgen-non-responsive cells .In particular, we have 
observed that DHT induced the expression of AR-regu-
lated prostate-specific antigen (PSA) and transmembrane 
protease serine 2 (TMPRSS2) genes in LNCaP cells, and 
only marginal increase was observed with PC-3 cells. The 
increased levels of TMPRSS2 were seen only in moder-
ately differentiated PCa cells. However, LNCaP cells are 
poorly differentiated and hence do not show significant lev-
els of TMPRSS2 mRNA which correlates with the findings 
of Rajput et al. [43]. These prostate-specific marker genes 
are known to be upregulated in a majority of prostate can-
cer patients [44]. In contrast, BIC significantly inhibited 
the expression of PSA and TMPRSS2 genes in LNCaP 
cells and this observation was in agreement with the ear-
lier studies [45]. However, DHT or BIC treatments show 
less or marginal effect on the expression of the above genes 
in PC-3 cells and this may be due to the difference in AR 
status.
AP-1 Protein expression of the oncogene Jun/Fes is 
widely associated with many types of cancers [19]. The 
cellular response mediated by AP-1 depends on the com-
plex interplay between the different dimers of the Jun and 
Fos family members [25, 46]. Expression of Fos and Jun 
may have a unique role in prostate tumorigenesis and rel-
evance to androgen receptor signaling. Specific AP-1 fam-
ily members have been shown to have an integral role in 
androgen-regulated prostate homeostasis, which may pro-
vide a mechanism by which they promote prostate tumori-
genesis and transformation into CRPC [47]. In the present 
study, we reported the expression pattern of all the AP-1 
factors (c-Jun, Jun-B, Jun-D and c-Fos, Fra-1, Fra-2, and 
Fos-B) in DHT- and BIC-treated PCa cells. Our studies 
revealed that DHT significantly induced c-Jun and Fra-1 
as key components of the AP-1 complex that underwent 
changes in LNCaP cells, whereas in PC-3 cells, it was 
found to be c-Jun and c-Fos. Our results correlate with 
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Fig. 8  Effect of DHT and BIC on mRNA levels of Apoptotic genes 
in (a) LNCaP cells and (b) PC-3 cells. LNCaP or PC-3 cells (5 × 105 
cells/well) were treated with or without DHT (10 nM) or BIC (50 
and 75 µM) for 48 h in a 6-well plate. Total RNA was isolated from 
cells and cDNA was prepared by RT and subjected to 30 cycles of 
PCR using specific primers of Apoptotic genes. Expression of β-actin 
was used as a positive control and for normalization. Data shown 
are mean ± SD from three independent experiments. Differences in 
Apoptotic gene mRNA levels are statistically significant: if *P < 0.05 
compared to control cells, #P < 0.05 compared with DHT-treated con-
dition values using one-way ANOVA followed by post hoc Tukey 
test. The bar graph represents the densitometric analysis of mRNA 
levels of Apoptotic genes
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the findings of Ouyang et al. [23] who reported that both 
c-Jun and c-Fos are upregulated in metastatic prostate 
cancer, and only high c-Jun expression is associated with 
poor prognosis. Our results are supported by the earlier 
findings that suppression of c-Jun using antisense RNA 
strongly compromised the androgen-dependent prolifera-
tion of LNCaP cells [36]. Similarly, patients with high 
expression levels of the active form of phosphorylated 
c-Jun had significantly shorter relapse-free survival times, 
compared with patients with low phosphorylated c-Jun 
protein expression, suggesting that increased active-c-
Jun levels may promote castration-resistant tumor growth 
[48]. Previous reports also demonstrate that constitutive 
activation of c-Jun, Fra-1, and Jun-D is associated with 
prostate cancer progression towards an androgen-inde-
pendent phenotype [49]. Treatment of BIC blocked the 
expression of mRNAs of C-Jun and Fra-1, and in turn also 
activated the expression of Jun-D in androgen-dependent 
LNCaP cells. However, in androgen-independent PC-3 
cells, BIC inhibited the expression of mRNAs of c-Jun 
and c-Fos with no effect on Jun-D and Fra-1 transcript. 
Previous investigation has shown that Fra-1 and Fra-2 
and their target genes might be involved in cell inva-
sion and migration [50]. However, Fra-1 was found to be 
increased in breast cancer where it functions as an onco-
gene to enhance tumor cell migration [51]. Similar effect 
of Fra-1 was observed with respect to LNCaP cells, and 
higher expression of both Fra-1 and Fra-2 was observed in 
PC-3 cells, compared to LNCaP, and Fra-1 may have mul-
tiple roles depending on the tumor type and conditions. 
In PC-3 cells, constitutive expression and non-respon-
siveness of Fra-1 transcript at both mRNA and protein 
level may probably lead to aggressive behavior of PC-3 
cells that needs to be investigated and confirmed using 
in  vivo model system. Many groups reported that Jun-D 
and Fra-2 are relevant in maintaining functional, differ-
entiated cells. For example, Jun-D and Fra-2 have been 
associated with growth inhibition/differentiation induced 
by various stimuli in a wide variety of cell types, such as 
mouse fibroblasts [52] muscle cells [53], and osteoblasts 
[54]; and human chronic myelogenous leukemia cells 
[55], intestinal epithelial cells [56], and ovarian cancer 
cells [57]. Overall, the results suggested that the differen-
tial expression of AP-1 factors may have role in the trans-
formation of more aggressive AR-negative PC-3 cells into 
CRPC that needs further investigation in in vivo models.
AP-1 factors control various cellular processes through 
their ability to regulate the expression and function of cell 
cycle regulators and apoptotic genes [16]. Our studies show 
that DHT induced the expression of cyclin E1 mRNA tran-
script, while BIC inhibited the expression of cyclin E1 in 
LNCaP cells. As studies have shown that cyclin E1 activity 
was required for cell cycle progression [58] and cyclin D1 
was shown to act as an AR co-repressor [59], we consid-
ered the possibility that cyclin D1 may mediate the inhibi-
tory effect in response to BIC treatment, while the non-
responsiveness of AR-negative PC-3 cell towards DHT on 
cell cycle regulation confirms that the cells probably lost 
the control over AR-regulated genes. However, BIC sig-
nificantly decreased the cyclin E1 mRNA levels suggesting 
that probably it is acting through non-genomic action via 
Ras/Raf/MAP kinase, PI3K, and PKC cascades that may 
influence cell cycle regulation and/or increase cell prolif-
eration through AP-1 transcription factors [60]. Both Bcl-2 
and Bax gene families acts as a key factor, and their ratio 
plays an important role in regulation of endogenous mito-
chondrial apoptosis pathway [61]. Our results depict that 
the BIC increased the pro-apoptotic Bax and decreased 
anti-apoptotic Bcl2 expression in both LNCaP and PC-3 
cells. Activation of both caspase-8 and 3 mRNAs follow-
ing the treatment with BIC in PC-3 and caspase-8 mRNA 
activation in LNCaP cells suggested that BIC induced the 
apoptosis via both extrinsic and intrinsic pathways.
In conclusion, our study demonstrated that there is a 
difference in expression of individual AP-1 transcription 
factors in androgen-dependent LNCaP and androgen-inde-
pendent PC-3 cells as these factors are stage-specific.DHT 
induced AR-activated AP-1 activity in AR-positive LNCaP 
cells, while in AR-negative PC-3 cells, it was AR-inde-
pendent activation of AP-1 activity. Further, BIC signifi-
cantly decreased Fra-1 transcript in LNCaP cells and found 
to have no effect in PC-3 cells suggesting that Fra-1 may 
play a key role in the development of androgen-independ-
ent PC-3 cells. Overall, findings from the present study 
support that Fra-1 could be an exciting target for prevention 
of transition to CRPC status with effective medication, and 
prostate cancer treatment.
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